Biotech entity
Every one of those 1 sits in a single category, pharma. Of the tracked stories, 1 of 1 also mention Catherine Hanaway, the most common co-covered peer. We currently track 1 Biotech story that mention telehealth, all published on March 13, 2026.
Last mentioned: Jun 28, 2026
Entity pulse
Coverage balance Negative coverage leads. Negative coverage exceeds positive coverage by 100 percentage points.
Figures are computed live from our source-verified story record — see our methodology for how impact and sentiment are derived.
Every one of those 1 sits in a single category, pharma. Of the tracked stories, 1 of 1 also mention Catherine Hanaway, the most common co-covered peer. We currently track 1 Biotech story that mention telehealth, all published on March 13, 2026. Each carries 2 original sources on average.
Computed from the 1 stories linked to this entity, with beat comparisons drawn from all 18 Biotech stories published in the same date window. Shares are omitted below five stories and comparisons below a twenty-story baseline.
Coverage cohort
Other entities that clear the same relevance threshold in stories also covering telehealth. Shared-story counts are live from our verified record — not editorial picks.
Missouri Pause Request
DOJ files a request in federal court to pause the Missouri-led lawsuit citing an ongoing FDA review.
Hawley Federal Bill
Senator Josh Hawley introduces a bill in the Senate to ban mifepristone nationwide.
Louisiana Pause Request
DOJ asks Louisiana to pause its separate lawsuit; request is rejected by AG Liz Murrill.
Missouri Lawsuit Filed
Missouri, Kansas, and Idaho file suit against the FDA to restrict mifepristone access.
The Department of Justice has requested a federal court to pause a multi-state lawsuit against the FDA regarding the abortion pill mifepristone. The move suggests a strategic effort to allow the FDA to conduct its own internal review of the drug's safety and distribution protocols.
telehealth is linked from 1 story on this site, each scored at or above our 35% relevance threshold — see how these pages are built.
See something wrong on this page — a misattributed entity, a wrong stat, a broken source link? Report a data issue.
